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Ranolazine and Silent Ischemia
I read with interest the paper by Stone et al. (1), in which the authors
investigated the relationship between ST-segment depression and the
rate-pressure product during exercise. Based on their findings, they
suggested that ranolazine’s beneficial action is most likely primarily
due to improvement of regional coronary blood flow in areas of
myocardial ischemia. I do not refute that statement, but I would like
to remind the readers that the current hypothesis of the mechanism of
action of ranolazine is that it works only after myocardial ischemia has
been present. When that happens, the late sodium channel remains
open, leading to intracellular sodium overload, and the sodium–
calcium exchanger then leads to intracellular calcium overload, which
results in increased calcium ions intracellularly and impaired diastolic
relaxation and increased tension. Ranolazine inhibits the myocardial
late inward sodium current associated with ischemia and thus breaks
up the cycle (2).
The authors emphasize in their article that under low stress conditions
of exercise where there was mild ischemia, the ranolazine did not seem to
be effective; however, as the ischemia became more pronounced, the
anti-ischemic effects of ranolazine became more marked.
My question to the investigators is this: Since it has been shown
many times that patients with chronic stable angina have multiple aepisodes of asymptomatic cardiac ischemia, is it possible or
probable that these multiple episodes of silent cardiac ischemia are
prevented from becoming manifest symptoms of myocardial isch-
emia (i.e., angina) by the drug ranolazine?
I suspect that the only way one could find the answer is to have
chronic ambulatory electrocardiogram (ECG) monitoring of these
patients. I know that patients who were in the MERLIN–TIMI
36 (Metabolic Efficiency With Ranolazine for Less Ischemia in
Non–ST-Segment Elevation Acute Coronary Syndromes–
Thrombolysis In Myocardial Infarction 36) trial (3) had 7 days of
ambulatory ECG monitoring, but the published study revealed
that only arrhythmias were assessed. Would it be possible to go
back and investigate those ambulatory ECGs to see whether or not
silent ST-segment depression was present on several occasions
without any manifestations of angina?
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Reply
Dr. Conti raises an interesting conceptual point regarding our paper
(1) concerning the implications of treatment with ranolazine. If
anolazine were to render each ischemic episode less severe than an
schemic episode in the absence of ranolazine, then despite a reduction
n symptomatic ischemia (i.e., angina), ranolazine may be associated
ith more frequent asymptomatic ischemia and, by inference, may
xpose the patient to an increased risk of cardiac events.
The fundamental premise implicit in this question, however,
hat asymptomatic episodes of myocardial ischemia represent less
evere ischemia than symptomatic episodes, has not been demon-
trated in any clinical study. Episodes of asymptomatic ischemia
ecorded during ambulatory electrocardiogram (ECG) recordings
emonstrate the same ECG characteristics of ischemia severity as
pisodes of symptomatic ischemia (2). There is no evidence to
upport the notion that asymptomatic ischemia is asymptomatic
ecause it is less severe than symptomatic ischemia and, conse-
uently, does not reach an “angina threshold.”
As Dr. Conti noted, patients in the MERLIN–TIMI 36 (Metabolic
fficiency With Ranolazine for Less Ischemia in Non–ST-Segment
levation Acute Coronary Syndromes–Thrombolysis In Myocardial
nfarction 36) trial had 7 days of continuous ECG recordings following
dmission with a non–ST-segment elevation acute coronary syndrome.
